Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose

详细信息    查看全文

• 作者：Po-Hsun Chen ; Yi-Ting Tsai ; Jun-Sing Wang ; Shi-Dou Lin…
• 关键词：Beta ; cell function ; Disposition index ; Glycated hemoglobin ; Glycemic control ; Metformin
• 刊名：Diabetology and Metabolic Syndrome
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：6
• 期：1
• 全文大小：234 KB
• 参考文献：1. DeFronzo, RA (2004) Pathogenesis of type 2 diabetes mellitus. Med Clin North A 88: pp. 787-835 CrossRef
  U.K. Prospective diabetes study 16. Overview of 6 years-therapy of type II diabetes: a progressive disease. Diabetes 44: pp. 1249-1258 CrossRef
  2. Levy, J, Atkinson, AB, Bell, PM, McCance, DR, Hadden, DR (1998) Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 15: pp. 290-296 CrossRef
  3. Wang, JS, Tu, ST, Lee, IT, Lin, SD, Lin, SY, Su, SL, Lee, WJ, Sheu, WH (2011) Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev 27: pp. 79-84 CrossRef
  4. Chan, JC, Malik, V, Jia, W, Kadowaki, T, Yajnik, CS, Yoon, KH, Hu, FB (2009) Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301: pp. 2129-2140 CrossRef
  5. Fukushima, M, Suzuki, H, Seino, Y (2004) Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 66: pp. S37-S43 CrossRef
  6. Inzucchi, SE, Bergenstal, RM, Buse, JB, Diamant, M, Ferrannini, E, Nauck, M, Peters, AL, Tsapas, A, Wender, R, Matthews, DR (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35: pp. 1364-1379 CrossRef
  7. Wang, JS, Lin, SD, Lee, WJ, Su, SL, Lee, IT, Tu, ST, Tseng, YH, Lin, SY, Sheu, WH (2011) Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Clin Ther 33: pp. 1932-1942 CrossRef
  8. Matthews, DR, Hosker, JP, Rudenski, AS, Naylor, BA, Treacher, DF, Turner, RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: pp. 412-419 CrossRef
  9. Matsuda, M, DeFronzo, RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: pp. 1462-1470 CrossRef
  10. Phillips, DI, Clark, PM, Hales, CN, Osmond, C (1994) Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 11: pp. 286-292 CrossRef
  11. Cobelli, C, Toffolo, GM, Dalla Man, C, Campioni, M, Denti, P, Caumo, A, Butler, P, Rizza, R (2007) Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 293: pp. E1-E15 CrossRef
  12. Maki, KC, Rains, TM, Dicklin, MR, Bell, M (2010) Repeatability of indices of insulin sensitivity and secretion from standard liquid meal tests in subjects with type 2 diabetes mellitus or normal or impaired fasting glucose. Diabetes Technol Ther 12: pp. 895-900 CrossRef
  13. Maki, KC, Kelley, KM, Lawless, AL, Hubacher, RL, Schild, AL, Dicklin, MR, Rains, TM (2011) Validation of insul
• 刊物主题：Diabetes; Metabolic Diseases; Endocrinology;
• 出版者：BioMed Central
• ISSN：1758-5996

文摘

Background This study aimed to explore parameters which will predict good control of HbA1c after adding a second anti-diabetic drug in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin monotherapy. Methods Fifty-one patients (M/F: 25/26, mean age: 53.7?±-.2?years, mean glycated hemoglobin [HbA1c] 8.4?±-.2%) with T2DM inadequately controlled with metformin were randomized to add-on glibenclamide or acarbose for 16?weeks. Before and after combination therapy, the subjects underwent a 2-hour liquid mixed meal tolerance test to determine insulin secretion (HOMA-β, insulinogenic index, and disposition index [DI]) and insulin sensitivity (HOMA-IR and Matsuda insulin sensitivity index). Results At baseline, there was a significant inverse relationship between DI120 and HbA1c (p--.001) in all subjects. The addition of glibenclamide and acarbose improved HbA1c significantly from 8.6?±-.6% to 7.4?±-.2% (p--.001), and from 8.2?±-.8% to 7.5?±-.8% (p--.001), respectively. In the glibenclamide group, DI120 significantly increased from 51.2?±-4.2 to 74.9?±-1.9 (p--.05), and in the acarbose group, from 62.5?±-1.4 to 91.7?±-6.2 (p--.05), respectively. Multiple regression analyses showed that both baseline HbA1c and DI120 independently predicted reduction of HbA1c as well as final HbA1c after combination therapy. Conclusions In patients with T2DM inadequately controlled with metformin, add-on oral anti-diabetic agent with glibenclamide or acarbose resulted in the significant HbA1c reduction and improvement of β-cell function. Subjects with greater baseline β-cell function reserve displayed better glycemic response in the combination therapy of metformin with glibenclamide or acarbose. Trial registration This study was registered in the ClinicalTrials.gov with registration number of NCT00417729.